Karl Nägler

Karl Nägler is the managing partner at Wellington Partners. Karl has been in this position since September 2011. Prior to that, they were a general partner at Ventech from September 2009 to September 2011. At Ventech, they led investments and represented Ventech on the boards of Prosonix, Covagen, Funxional Therapeutics, and Themis. Karl also represented Ventech on the board of Actogenix.

Before joining Ventech, Karl was a postdoctoral research scientist at CNRS Centre de Neurochimie from August 2001 to January 2002. After that, they became a principal at Atlas Venture from February 2002 to September 2009. At Atlas Venture, they led financings and represented Atlas on the boards of Nitec Pharma, Egalet, and U3 Pharma.

Before their venture capital career, Karl worked as a research scientist at the Max Delbrueck Center from January 1999 to July 2001.